齐拉西酮与利培酮治疗女性精神分裂症对照研究

A control study on Ziprasidone versus Risperidone in the treatment of female schizophrenic

目的:比较齐拉西酮与利培酮治疗女性精神分裂症患者的疗效及不良反应。方法:将60例女性精神分裂症患者随机分成两组,分别给予齐拉西酮与利培酮治疗8周。采用阳性症状与阴性症状(PANSS)及不良反应量表(TESS)于治疗前及疗后2、4、8周末评估疗效和不良反应。结果:两组有效率分别为83.33%和86.67%,无显著差异(P>0.05),两药治疗女性精神分裂症疗效相当;齐拉西酮较少引起锥体外系反应(EPS),较少出现月经周期的改变。结论:齐拉西酮疗效和利培酮相当,且不良反应轻,是治疗女性精神分裂症患者的较好选择。

Objective：To compare the efficacy and adverse events of Ziprasidone and Risperidone in the treatment of female schizophrenic. Methods ：60 female schizophrenic were randomly divided into two groups for 8 weeks. One group was treated with Ziprasidone, another with Risperidone. The clinical efficacy and side effects were evaluated with positive and negative symptom scale （PANSS） and treatment emergent symptom scale （TESS） before and after 2,4,8 week treatments respectively. Results： Total effective rates of two groups were 83.33% and 86.67% respectively, which showed no difference （ P 〉 0.05 ） , The efficacies of both drugs in treatment of schizophrenic in female were similar; the Ziprasidone group showed lower scores in extra -pyramidal symptoms and menstruation change. Conclusions ： Ziprasidone, as well as Risperidone, was well efficient in the treatment of female schizophrenic, with slight side effects, so it can be as a better choice for the female patients with schizophrenia.